{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-021978","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.513728+00:00","generated_at":"2026-05-18T09:35:12.351611+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Dyadic rebrands as Dyadic Applied BioSolutions; highlights $250K milestone & $1.5M Gates grant","bullets":["Will do business as Dyadic Applied BioSolutions effective in 30 days; legal name unchanged.","Reports $250,000 milestone payment for second non-animal dairy enzyme program.","Received second $1.5M installment from $3.0M Gates Foundation grant for malaria/RSV mAbs.","Company shifts from research-driven to commercially focused enterprise on non-therapeutic proteins.","Targets commercialization of input proteins in 2025; C1 and Dapibus platforms are core."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-021978","json":"https://secwatch.observer/filing/0001437749-25-021978.json","markdown":"https://secwatch.observer/filing/0001437749-25-021978.md","text":"https://secwatch.observer/filing/0001437749-25-021978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774925021978/0001437749-25-021978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774925021978/dyai20250702_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:35:12.351611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}